Different Strategies to Execute Multi‐Database Studies for Medicines Surveillance in Real‐World Setting: A Reflection on the European Model
Open Access
- 3 April 2020
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (2), 228-235
- https://doi.org/10.1002/cpt.1833
Abstract
Although postmarketing studies conducted in population‐based databases often contain information on patients in the order of millions, they can still be underpowered if outcomes or exposure of interest is rare, or the interest is in subgroup effects. Combining several databases might provide the statistical power needed. A multi‐database study (MDS) uses at least two healthcare databases, which are not linked with each other at an individual person level, with analyses carried out in parallel across each database applying a common study protocol. Although many MDSs have been performed in Europe in the past 10 years, there is a lack of clarity on the peculiarities and implications of the existing strategies to conduct them. In this review, we identify four strategies to execute MDSs, classified according to specific choices in the execution: (A) local analyses, where data are extracted and analyzed locally, with programs developed by each site; (B) sharing of raw data, where raw data are locally extracted and transferred without analysis to a central partner, where all the data are pooled and analyzed; (C) use of a common data model with study‐specific data, where study‐specific data are locally extracted, loaded into a common data model, and processed locally with centrally developed programs; and (D) use of general common data model, where all local data are extracted and loaded into a common data model, prior to and independent of any study protocol, and protocols are incorporated in centrally developed programs that run locally. We illustrate differences between strategies and analyze potential implications.Keywords
This publication has 42 references indexed in Scilit:
- How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013BioDrugs, 2015
- Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling designBMJ, 2015
- Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?Journal of Internal Medicine, 2014
- Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment CommitteeNature Reviews Drug Discovery, 2014
- Population-based analysis of non-steroidal anti-inflammatory drug use among children in four European countries in the SOS project: what size of data platforms and which study designs do we need to assess safety issues?BMC Pediatrics, 2013
- Monitoring product safety in the postmarketing environmentTherapeutic Advances in Drug Safety, 2013
- The Nordic prescription databases as a resource for pharmacoepidemiological research—a literature reviewPharmacoepidemiology and Drug Safety, 2013
- Automating classification of free‐text electronic health records for epidemiological studiesPharmacoepidemiology and Drug Safety, 2012
- Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in EuropeBMJ, 2011
- Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR ProjectPharmacoepidemiology and Drug Safety, 2010